Per feedback from our community of oncologist members, Primum has added support for lung cancer virtual curbside consults.
Why did we add lung cancer specialists?
Approximately 240,000 lung cancer cases were forecasted to be diagnosed in 2022, comprising roughly 12% of all incident cancer cases.1 This incidence translates to lung cancer being the 3rd most common form of cancer in the US. Despite, its relative commonality the 5-year survival rate of lung cancer is lower than other malignancies. For example, Multiple Myeloma has a 58% 5-year survival rate whereas the 5-year relative survival rate of lung cancer is ~23%2. This lower survival rate highlights the fast-moving nature of lung cancer.
Lung cancer treatment is an essential focus of community oncologists. The treatment paradigm is driven by using diagnostic tests to identify genetic mutations that can be targeted with chemotherapy. As a result, we’ve heard that Primum could assist when using the results of diagnostic tests to create a patient treatment plan. Also, Primum could be helpful when determining which therapeutic option to use given recent approvals, like the recent pembrolizumab approval (See links to Twitter discussion about this approval here and here).